Cresilon Funding: How Much Did They Raise & Key Investors

How Much Did Cresilon Raise?
Funding & Key Investors

Cresilon, a Brooklyn-based pioneer in the biotechnology sector, has successfully secured a significant capital injection, bringing its total funding to $68.8M. This latest infusion of $5M represents a major strategic investment that underscores the market confidence in the company's proprietary hydrogel technology. By consistently attracting institutional backing, Cresilon continues to solidify its trajectory as a leader in the development and commercialization of advanced hemostatic medical devices.

The company's financial history reflects a disciplined approach to growth, beginning with early debt financing in 2020, followed by a substantial Series A round in 2021, and subsequent strategic financing rounds. This progression highlights a robust capital structure designed to support long-term research, development, and market expansion within the highly competitive medical technology landscape.

What is Cresilon?

Cresilon

Manufacturing

Medical Devices & Equipment

Business Services

Founded in 2010, Cresilon operates at the intersection of material science and clinical medicine. The company specializes in the engineering of proprietary hydrogel-based solutions that address critical needs in hemostasis, effectively managing bleeding in surgical and trauma settings. By leveraging its unique technological platform, Cresilon has positioned itself as a disruptive force in the medical device industry, moving beyond traditional wound care to provide high-performance, rapid-acting solutions that improve patient outcomes and streamline clinical workflows. Its commitment to manufacturing excellence and rigorous clinical validation has established the firm as a critical player in the global healthcare supply chain.

How much funding has Cresilon raised?

Cresilon has raised a total of $68.8M across 4 funding rounds:

2020

Debt

$350K

2021

Series A

$38.5M

2022

Other Financing Round

$25M

2026

Debt

$5M

Debt (2020): $350K with participation from PPP

Series A (2021): $38.5M, investors not publicly disclosed

Other Financing Round (2022): $25M supported by Paulson Investment Company

Debt (2026): $5M, investors not publicly disclosed

Key Investors in Cresilon

Paulson Investment Company

Paulson Investment Company is a boutique investment banking and broker-dealer firm that focuses on serving small and mid-sized companies through capital markets expertise and long-term financial advisory services.

PPP

Public-Private Partnership

Undisclosed Investors

What's next for Cresilon?

With this latest major strategic investment, Cresilon is well-positioned to accelerate its commercial scaling efforts and expand its footprint in both domestic and international markets. The company is expected to prioritize the optimization of its manufacturing capabilities to meet rising demand for its hydrogel products while simultaneously advancing its pipeline of next-generation medical devices. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward deepening its clinical evidence base and securing broader regulatory approvals, thereby enhancing its competitive moat and long-term valuation potential in the biotechnology sector.

See full Cresilon company page

See More Financial Insights